Lilly’s Antibody Clinical Trial in Nursing Homes Prevents COVID
A Phase 3 clinical trial of an antibody-drug that enrolled residents and staff at skilled nursing and assisted living facilities found that the treatment significantly reduced the risk of contracting symptomatic COVID-19.